Full Text | PDF

Share on facebook Share on tweeters Share on linkedin Share on googleplus

Theranostics 2019; 9(22):6532-6549. doi:10.7150/thno.35057 This issue Cite

Research Paper

A stage-specific cancer chemotherapy strategy through flexible combination of reduction-activated charge-conversional core-shell nanoparticles

Lingfei Han1, Yingming Wang1, Xiaoxian Huang2, Bowen Liu2, Lejian Hu2, Congyu Ma1, Jun Liu3, Jingwei Xue3,4, Wei Qu2, Fulei Liu2,3,5✉, Feng Feng2,6✉, Wenyuan Liu1,7✉

1. Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China
2. Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China
3. The Joint Laboratory of Chinese Pharmaceutical University and Taian City Central Hospital, Taian City Central Hospital, Taian, 271000, China
4. Taian City institute of Digestive Disease, Taian City Central Hospital, Taian, 271000, China
5. Pharmaceutical Department, Taian City Central Hospital, Taian, 271000, China
6. Jiangsu Food and Pharmaceutical Science College, Huaian 223003, China
7. Hangzhou Institute of Pharmaceutical Innovation, China Pharmaceutical University, Hangzhou 310018, China

✉ Corresponding authors: liu_fuleicom; fengsunlightcom; liuwenyuan8506com.

Citation:
Han L, Wang Y, Huang X, Liu B, Hu L, Ma C, Liu J, Xue J, Qu W, Liu F, Feng F, Liu W. A stage-specific cancer chemotherapy strategy through flexible combination of reduction-activated charge-conversional core-shell nanoparticles. Theranostics 2019; 9(22):6532-6549. doi:10.7150/thno.35057. https://www.thno.org/v09p6532.htm
Other styles

File import instruction

Abstract

Graphic abstract

Precision medicine has increased the demand for stage-specific cancer chemotherapy. Drugs with different properties are needed for different stages of tumor development, which is, inducing rapid destruction in the early stage and facilitating deep penetration in the advanced stage. Herein, we report a novel reduction-activated charge-conversional core-shell nanoparticle (CS NP) formula based on ring-closing metathesis of the thiamine disulfide system (TDS) to deliver the chemotherapeutic agent-gambogic acid (GA).

Methods: The shell consisted of hyaluronic acid-all-trans retinoid acid with a disulfide bond as the linker (HA-SS-ATRA). The core was selected from poly (γ-glutamic acid) with different grafting rates of the functional group (Fx%) of TDS. GA/CF100%S NPs, with the strongest reduction-responsive drug release, and GA/CF60%S NPs with the strongest penetration have been finally screened. On this basis, a stage-specific administration strategy against a two-stage hepatocellular carcinoma was proposed.

Results: The developed CS NPs have been confirmed as inducing reduction-activated charge conversion from about -25 to +30 mV with up to 95% drug release within 48 h. The administration strategy, GA/CF100%S NPs for the early-stage tumor, and sequential administration of GA/CF60%S NPs followed by GA/CF100%S NPs for the advanced-stage tumor, achieved excellent tumor inhibition rates of 93.86±2.94% and 90.76±6.43%, respectively.

Conclusions: Our CS NPs provide a novel platform for charge conversion activated by reduction. The stage-specific administration strategy showed great promise for cancer therapy.

Keywords: charge conversion, reduction-activated, tumor penetration, stage-specific chemotherapy, hepatocellular carcinoma

Citation styles

APA
Han, L., Wang, Y., Huang, X., Liu, B., Hu, L., Ma, C., Liu, J., Xue, J., Qu, W., Liu, F., Feng, F., Liu, W. (2019). A stage-specific cancer chemotherapy strategy through flexible combination of reduction-activated charge-conversional core-shell nanoparticles. Theranostics, 9(22), 6532-6549. https://doi.org/10.7150/thno.35057.

ACS
Han, L.; Wang, Y.; Huang, X.; Liu, B.; Hu, L.; Ma, C.; Liu, J.; Xue, J.; Qu, W.; Liu, F.; Feng, F.; Liu, W. A stage-specific cancer chemotherapy strategy through flexible combination of reduction-activated charge-conversional core-shell nanoparticles. Theranostics 2019, 9 (22), 6532-6549. DOI: 10.7150/thno.35057.

NLM
Han L, Wang Y, Huang X, Liu B, Hu L, Ma C, Liu J, Xue J, Qu W, Liu F, Feng F, Liu W. A stage-specific cancer chemotherapy strategy through flexible combination of reduction-activated charge-conversional core-shell nanoparticles. Theranostics 2019; 9(22):6532-6549. doi:10.7150/thno.35057. https://www.thno.org/v09p6532.htm

CSE
Han L, Wang Y, Huang X, Liu B, Hu L, Ma C, Liu J, Xue J, Qu W, Liu F, Feng F, Liu W. 2019. A stage-specific cancer chemotherapy strategy through flexible combination of reduction-activated charge-conversional core-shell nanoparticles. Theranostics. 9(22):6532-6549.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use